Search results

We've been quite busy answering questions about coronavirus, UV light, and hand sanitizer.

In the Digital Age, we have access to more information than at any time in human history. But that doesn't stop the spread of conspiracy theories. Here are the best (worst?) ones involving the new coronavirus and the disease COVID-19.

Remdesivir, an antiviral drug that many are pinning their hopes on to help solve this pandemic nightmare, is now being tested in hundreds of trials. Results are expected within weeks. But the drug has already been tested in monkeys. And it worked.

Bad luck played a role in the COVID-19 pandemic, but China's criminally negligent and malevolent behavior has placed the world in a position in which bad things are likelier to occur. Therefore, China must bear the brunt of the blame, and our relationship with that country should not go back to normal.

Scammers like to scare the elderly using coronavirus and Social Security fraud. Now, the AARP likes to scare old people over the food they eat.

Preliminary data, obtained from a randomized clinical trial of remdesivir in China, look bad. Maybe even very bad. But this doesn't mean that the drug won't be shown to be useful in other trials. Nonetheless, not good news.

Much remains unknown about the coronavirus. A new paper published in The Lancet estimates that roughly 60% of the population needs to be immune to COVID-19 to achieve herd immunity.

The global mortality rate from air pollution is estimated to be 8.8 million people per year. That's 18% higher than the 7.2 million lost annually from tobacco. Do you believe it? There is room for doubt. Let's take a look.

The world anxiously awaits while clinical trials of remdesivir are in progress. The drug failed to stop Ebola. Does this mean it will also fail to stop coronavirus? No. According to a new study in the Journal of Biological Chemistry, the drug should work better. Here's why.

How would we respond differently if another outbreak happened?

Niche; it can be described as a comfortable, suitable position in life, the equipoise of resources and competition. Having one’s niche, it sounds so comforting; having a special place in the world. COVID-19 may have temporarily disrupted our niche, but climate change could drastically re-alter it.

Once again, from the frontline of COVID-19's war on the elderly, a follow-up diary covering recent thoughts of two of our seniors. They are heroes in their own way.

Media headlines are almost exclusively about the coronavirus death toll and the debate over whether it's too early to begin lifting lockdown restrictions. However, there are several other observations about COVID-19 that are important, but are getting very little attention.

As a result, we're now paying the price for perverse, wasteful research spending.

Every morning we're greeted by another set of indicators telling us how bad or good the COVID-19 pandemic is trending. There are lots of numbers to consider, but which are actually useful?

Somewhere along the way, our achievable goal of "flattening the curve" for COVID-19 has mutated into "finding a cure," which is perhaps an impossible one. Public health and economic policy must be based on reality, not starry-eyed wish-making. Otherwise, people's lives and livelihoods are in grave danger.

American culture, specifically our disdainful attitude toward expertise and leadership, is not conducive to making improvements to public health policy. Don't expect many changes in response to the coronavirus pandemic.

Another “novel” feature of COVID-19 is coming to our attention: some individuals are more capable than others of sharing their viral load and infecting others. What’s up with that? Let's take a look.

Given that PBS, in its recent documentary, “The Man Who Tried to Feed the World,” found it necessary to disparage Nobel Laureate Dr. Norman Borlaug, we believe it is important for our readers, and the world, to know what a thoughtful and truly benevolent man he actually was. Here is an article about Dr. Borlaug, a co-founder of the American Council on Science and Health, that we published on July 18, 2007 after first appearing in the Washington Times earlier that day.

Is sticking your finger down your throat a pleasant experience? How about sticking it down there and leaving it for three weeks? You probably wouldn't want to be awake for that, but a shortage of IV hospital drugs is causing some real problems for intubated patients on ventilators. And guess what drug they're out of? Fentanyl(!). And if you read on you'll get that, plus a bubble bath with Kim Jong-un, all in one idiotic article.

Publishing propaganda as news is dishonest and lets readers down. Dr. Henry Miller (pictured), the founding director of the FDA's Office of Biotechnology, explains.

The BBC reports that the first life-saving drug for COVID-19 has been identified. While that is strictly true, without more context and numbers the impact of dexamethasone is obscured. Is this drug just click-bait material or actually a "major breakthrough"?

Many in mainstream media recently reported on the possibility of COVID-19 being transmitted during the flush of a toilet. While the physics involved appeared to be well modeled, the biologic implications are fuzzy at best. Here's how this scenario plays out.

As we re-open society, science is beginning to return to some of its older memes, like the value of nutritional labeling and taxes. Two new studies by authors, using the same model and data, suggest that fully implementing labeling laws will improve our health and save us money. The same holds for taxing sugary beverages. But if COVID-19 has taught us nothing else, it is that we need to understand and believe the model's assumptions.

Timothy Litzenburg, one of the lead plaintiffs' attorneys in the shakedown of Monsanto, has pleaded guilty to the attempted extortion of $200 million from another company. Litzenburg also collaborates with Carey Gillam and her anti-GMO organization U.S. Right to Know.